Over $40M in Funding Propels Neuropathy Therapy to Phase 3 Clinical Trials
$40M
Non-dilutive funding awarded
WinSanTor’s founders from the University of Winnipeg, the University of California at San Diego, and the University of Toronto had extensive academic grant writing experience. However, they were unfamiliar with the SBIR/STTR program, and so in 2014, they engaged EGC to prepare an NIH SBIR Fast-Track proposal. This partnership enabled WinSanTor to secure a Fast-Track award on their first attempt, providing $2.3 million at a critical time in the company’s development. In the subsequent 10 years, through a continued partnership with EGC, WinSanTor has raised over $40 million in funding from United States and Canadian government grants.
With most of its funding coming from non-dilutive sources, WinSanTor has made significant progress in developing the first disease-modifying treatment for neuropathy.
In 2024, WinSanTor’s CEO, Stan Kim, discussed the company’s success in securing funding at the Redefining Early Stage Investments (RESI) conference in San Francisco. Mr. Kim credited EGC with much of the company’s ability to raise funds from non-dilutive sources during a time when the company’s technology was too early to attract equity financing. EGC is excited to continue our partnership with WinSanTor as they enter into Phase 3 clinical trials for their groundbreaking treatment for neuropathy.
“Our company exists today because of EGC. They helped us turn over every rock, and with their help, we’ve received tens of millions of dollars of funding that literally kept the company afloat. They have an amazing team, which we now consider part of our own company as far as desire and commitment.”
– Stanley Kim, CEO, WinSanTor
Funding Sources
